Previous investigations into potential transforming activities of adenovirus (Ad) early genes were largely overshadowed by the more obvious roles of E1A and E1B products. One exception was an Ad9 E4 protein (ORF1) shown to enhance transformation of cultured cells and promote mammary tumors in female rats. Recently, signi®cant advances in understanding Ad E4 gene products at the molecular level have revealed that these proteins possess an unexpectedly diverse collection of functions, which not only orchestrate many viral processes, but overlap with oncogenic transformation of primary mammalian cells. Operating through a complex network of protein interactions with key viral and cellular regulatory components, Ad E4 products are apparently involved in transcription, apoptosis, cell cycle control, DNA repair, cell signaling, posttranslational modi®cations and the integrity of nuclear multiprotein complexes known as PML oncogenic domains (PODs). Some of these functions directly relate to known transforming and oncogenic processes, or implicate mechanisms such as modulating the function and subcellular localization of cellular PDZ domain-containing proteins, POD reorganization, targeted proteolytic degradation, inhibition of DNA double-strand break repair and`hit-and-run' mutagenesis. Here, we summarize the recent data and discuss how E4 gene product interactions may contribute to viral oncogenesis. Oncogene (2001) 20, 7847 ± 7854. 
Introduction
Members of the family Adenoviridae infect a wide range of mammalian and avian hosts causing lytic and persistent infections. In humans they are associated with a variety of clinical syndromes (reviewed in Horwitz, 1996) , with over 50 distinct adenovirus (Ad) serotypes having been identi®ed and allocated to six subgroups (A through F). Although these viruses are not associated with human cancers, a subset of them, including all subgroup A and B viruses have the capacity to promote tumors (mostly undierentiated sarcomas) in both male and female rodents at the site of injection (reviewed in Graham, 1984) . Their transforming and oncogenic properties have been traditionally ascribed to functions in early region 1 (E1) which encodes the classical Ad E1A and E1B oncoproteins (reviewed in Nevins and Vogt, 1996) . Although subgroup D Ads are non-oncogenic in hamsters (Trentin et al., 1962) , subgroup D Ad9 elicits exclusively estrogen-dependent mammary tumors in female rats following subcutaneous or intraperitoneal injection (Javier et al., 1991; Javier and Shenk, 1996) . Besides its unique oncogenicity, Ad9 is unusual among Ads in requiring viral functions located outside of the E1 region for tumor induction (Javier et al., 1992) . Several studies have now established that its tumorigenicity in animals is solely dependent on two viral early region 4 (E4) encoded functions, the product of open reading frame (ORF) 1 (Javier, 1994) and some unde®ned regulatory element overlapping ORF2 (Thomas et al., 1999 (Thomas et al., , 2001 . Recent work suggests that transformation by this viral oncoprotein diers considerably from the E1 encoded functions and is mediated through a novel mechanism that may also play a role in the transformation by the high-risk human papillomavirus (HPV) E6 proteins (Lee et al., 1997 Gardiol et al., 1999; Glaunsinger et al., 2000) . Furthermore, ORF1 products from Ad9 and several non-subgroup D Ads can transform human cells in culture, indicating that E4 ORF1 is a transforming protein in a variety of human Ad serotypes (Weiss et al., 1997b) . Similar to E4 ORF1 other studies have shown that the ORF3 and ORF6 proteins from the non-oncogenic subgroup C Ad5 exhibit characteristic features of viral growth-transforming proteins. Each E4 gene product substantially enhances transformation of primary rat cells in cooperation with E1A plus E1B proteins (Moore et al., 1996; Nevels et al., 1997 Nevels et al., , 1999b , and confers multiple additional transformed properties on E1-expressing cells, including dramatically accelerated tumor growth in nude mice (Nevels et al., 1999a,b) . Also E4 ORF3 and E4 ORF6 can individually replace the function of E1B proteins to initiate focal transformation of primary rat cells in conjunction with E1A alone. Interestingly, the majority of these cells lack E1A-and E4-speci®c sequences indicating that transformation occurred through a`hit-and-run' mechanism (Nevels et al., 2001) . These observations together with the ®ndings for E4 ORF1 contradict the conventional concept of Ad-induced transformation (reviewed in Graham, 1984) and support the idea that the oncogenic potential of human Ads is not exclusively determined by the E1A and E1B gene products. In this article we will summarize the current information that relates to E4 gene function in viral oncogenesis. Additional information addressing the role of E4 proteins in lytic infection may be found in other recent reviews (Kleinberger, 2000; Dobner and Kzhyshkowska, 2001; TaÈ uber and Dobner, 2001 ).
E4 gene products in viral oncogenesis
The Ad E4 transcription unit is located at the right-end of the Ad genome and is transcribed in the leftward direction (Figure 1 ). The E4 region from the most widely studied subgroup C Ads type 2 and 5 encodes at least six distinct polypeptides de®ned as E4 ORF1 to E4 ORF6/7 according to the order and arrangement of the corresponding open reading frames. Analyses of other serotypes indicate that all human Ads characterized so far have a homologous E4 region with similar sequence organization. E4 proteins encompass a diverse collection of functions required for ecient viral replication operating at all levels along the gene expression pathway through a complex network of protein interactions with key viral and cellular components (reviewed in TaÈ uber and .
The ®rst evidence that E4-encoded functions may play a role in Ad transformation originates from several ®ndings describing the presence of E4-speci®c mRNAs, in addition to E1A and E1B transcripts, in some Ad12 and Ad2/5 transformed cells (Flint et al., 1975 Esche et al., 1979; Esche, 1982; Esche and Siegman, 1982) , the detection of antibodies against E4 proteins in some tumor sera (Brackmann et al., 1980; Sarnow et al., 1982; Downey et al., 1983) and the observation that tumor induction by Ad virions is not determined by the gene products of E1 alone (Bernards et al., 1984; Zalmanzon, 1987) . Further analyses showed that coexpression of E1 and E4 from the highly oncogenic Ad12 in rat 3Y1 cells generated a completely transformed phenotype resulting in colony formation in soft-agar, as well as increased tumorigenic capacity (Shiroki et al., 1984) . Similarly, the entire E4 region from Ad2 was found to alter the morphology and stimulate anchorage-independent growth of Ad2 E1-transformed rat CREF ®broblasts (O È hman et al., 1995) . Although some of these properties were subsequently attributed to E4 ORF1 and ORF6, no single E4 ORF expressing plasmid was able to reproduce the large dense foci phenotype typical of the E1-cotransfected, entire E4- Figure 1 The genomic organization of Ad5 and the E4 transcription unit. Top: The linear double-stranded genome is depicted in the center as a thin line, with the inverted terminal repeats (ITR) at each end: lengths are marked in kbp. Early transcription units are shown relative to their position and orientation in the Ad5 genome: early genes E1A, E1B, E2A, E2B, E3 and E4 indicated by black bars. Genes expressed at intermediate times of infection (IX and IVa2) are indicated by gray bars. Open rectangles denote introns. Late genes (L1 ± L5) produced from the major late promoter (MLP) all contain the tripartite leader (TPL) at their 5' ends and are shown at the top of the ®gure. Small arrows denote virus-associated RNAs I and II (VA RNAs). Bottom: The Ad5 E4 transcription unit is enlarged with lengths in bp. The E4 unit is controlled by the E4 promoter (P) and generates a primary transcript of approximately 2800 nucleotides in length. This transcript is subject to a complex pattern of dierential splicing producing at least 18 distinct mRNAs that share common 5'-and 3'-terminal sequences (Herisse et al., 1981; Virtanen et al., 1984; Freyer et al., 1984) . The predicted seven dierent polypeptides are shown as open boxes. With the exception of ORF3/4, the products of ORF1, ORF2, ORF3, ORF3/4, ORF4, ORF6 and ORF6/7 have been reported to exist in infected cells (Downey et al., 1983; Sarnow et al., 1984; Cutt et al., 1987; Kleinberger and Shenk, 1993; Javier, 1994; Dix and Leppard, 1995; Thomas et al., 2001) . (Adapted from a previously published ®gure, Dobner and Kzhyshkowska, 2001) cotransformed CREF cells (O È hman et al., 1995) . Therefore, although not essential for non-subgroup D Ad oncogenesis, it has been proposed that E4 proteins have partial transforming activities (at least ORF1 and ORF6) that are able to stimulate E1 transformation and contribute to the transformed cell phenotype (O È hman et al., 1995) .
E4 ORF1
Compared with the subgroup A and B Ads, subgroup D Ad9 is unique in eliciting only estrogen-dependent mammary tumors in female rats (Ankerst et al., 1974; Jonsson and Ankerst, 1977; Ankerst and Jonsson, 1989; Javier et al., 1991) . By generating hybrids between Ad9 and the closely related non-tumorigenic Ad26 viruses the Ad9 oncogenic determinant was localized to a segment in the viral E4 region containing ORF1, ORF2 and ORF3 (Javier et al., 1991 (Javier et al., , 1992 Javier, 1994; Javier and Shenk, 1996) . The minimal essential E4 region was recently mapped to ORF1 and a previously unde®ned regulatory element overlapping ORF2. Although the contribution of this second nonprotein function to transformation is unknown, it was suggested to involve posttranscriptional control of speci®c E4 region mRNA abundance in cells, possibly altering expression of one or more E4 proteins, such as ORF3 (Thomas et al., 1999 (Thomas et al., , 2001 ). This observation is of particular interest since a recent study has shown that ORF3 is dispensable for Ad9-induced tumorigenesis and antagonizes this process (Thomas et al., 2001) . A mutant virus lacking Ad9 ORF3 causes mammary tumors in male rats with a frequency of 100%. Since tumors induced by Ad9 are known to be absolutely dependent on estrogen for growth and maintenance this not only suggests that ORF3 is responsible in part for the strict estrogen dependence of Ad9-induced mammary tumorigenesis, but reveals an activity that attenuates the response of the estrogen receptor to its hormone ligand in mammary cells. Although clearly still speculative, the contribution of Ad9 ORF3 to this process may be linked to ORF3-dependent reorganization of PODs as discussed below, and the recently reported modulation of a nuclear hormone-responsive promoter (Wienzek and Dobbelstein, 2001) .
Why Ad9 generates only mammary tumors in rats remains unclear. An E1A-substitution Ad5 vector expressing Ad9 E4 ORF1 ± but not the control Ad26 E4 ORF1 protein ± is tumorigenic in rats, and induces only Ad9-like mammary tumors (Thomas et al., 2001) . This implies that it is speci®cally Ad9 ORF1-associated functions that promote tumorigenesis in cells of the rat mammary gland, and not dierences related to cell tropism, and/or transcriptional regulation in estrogen hormone-receptor expressing cells. Alone, Ad9 E4 ORF1 expressed from the cytomegalovirus (CMV) early promoter is sucient for CREF cell transformation in vitro (Javier, 1994) , conferring multiple general transforming properties, and increasing the tumorigenic potential of CREF cells in vivo (Weiss et al., 1996) . Interestingly, however, while ORF1 products from viruses other than Ad9 exhibit weak transforming activity in CREF cells (Javier, 1994) the same proteins alone can transform human TE85 cells (Weiss et al., 1997b) . Their transforming activity directly correlates with signi®cantly increased protein levels in human cells compared to rat cells. This implies that all Ad ORF1 gene products possess cellular growth-transforming activities when their expression reaches some threshold level (Weiss et al., 1997b) .
The amino acid sequences of the predicted E4 ORF1 polypeptides show signi®cant similarity, ranging from 45 ± 51% identity (Weiss et al., 1997b) , and exhibit substantial similarity to a variety of animal and viral dUTP pyrophosphatase (dUTPase) enzymes, including a dUTPase encoded by the avian Ad CELO (Weiss et al., 1997b) . Not only structurally and evolutionarily related to important enzymes of nucleotide metabolism and DNA replication, the human Ad E4 ORF1 proteins apparently interact with a similar set of cellular factors. In vitro and in vivo binding studies show that ORF1 proteins from Ad9, Ad5 and Ad12 interact with a select group of PDZ domain-containing cellular products, including DLG, MUPP1 and MAGI-1 (Lee et al., 1997 Weiss and Javier, 1997; Glaunsinger et al., 2000) . PDZ-containing proteins represent a diverse family of polypeptides generally acting as scaolding proteins in cell signaling, partly through their ability to localize membrane and cytosolic proteins to the plasma membrane at specialized regions of cell-cell contact (Fanning and Anderson, 1999) . These ®ndings argue that E4 ORF1 products from human Ads target cellular proteins involved in cell signaling and signal transduction.
Three separate regions of Ad9 ORF1 (Figure 2 ) have been implicated as being critical for CREF cell transformation Weiss et al., 1997a) . While the functions of regions I and II are still unknown, region III at the extreme carboxy-terminus ± containing the functional PDZ domain-binding motif X S/T X (VIL) ± is involved in the proper cytoplasmic localization of Ad9 E4 ORF1 . Several lines of evidence indicate that interactions with multiple cellular polypeptides, particularly with the PDZ-domain containing proteins DLG, MAGI-1 and Lee et al., 1997 Lee et al., , 2000 Glaunsinger et al., 2000) are critical for Ad9 E4 ORF1-mediated transformation . First, DLG, a functional homologue of the Drosophila discs large (dlg) tumor suppressor protein is also a cellular target for the Tax oncoprotein of human T-cell leukemia virus type 1 (HTLV-1) and the E6 oncoproteins of high-risk human papillomaviruses (HPV), both of which target DLG for proteasomal degradation (Gardiol et al., 1999) . Second, the DLG-related polypeptide MAGI-1 and the widely expressed cellular factor MUPP1 are both aberrantly sequestrated by Ad9 E4 ORF1 in the cytoplasm: the high-risk HPV E6 proteins also direct these cellular proteins into the proteasome degradation pathway. Third, these eects are speci®c since Ad9 ORF1 and high-risk HPV E6 mutant viral proteins unable to bind MUPP1 and MAGI-1 lack these activities Lee et al., 2000) . Taken together these results demonstrate that the transforming activities of Ad9 E4 ORF1, and presumably other Ad ORF1 products, dier fundamentally from those of the E1A and E1B oncoproteins. To some extent this mechanism resembles the inactivation of tumor suppressor protein p53 by Ad2/5 large E1B and high-risk HPV E6 proteins, providing another example of unrelated viral oncoproteins apparently evolving to target the same cellular factors.
E4 ORF3 and E4 ORF6
Initial attempts to assign speci®c functions to E4 gene products in virus-infected cells revealed that ORF3 and ORF6 can partially or totally compensate for each other's defects (reviewed in Dobner and Kzhyshkowska, 2001; TaÈ uber and Dobner, 2001) . Each E4 protein independently augments viral DNA replication, late viral protein synthesis, shut-o of host protein synthesis or production of progeny virions, and inhibits concatemer formation of viral genomes (Halbert et al., 1985; Ketner, 1989, 1990; Huang and Hearing, 1989a; Weiden and Ginsberg, 1994) . More recent evidence suggests that some of the redundant functions shared by both E4 proteins are linked to their ability to interact with common cellular and viral factors. For example, Ketner and coworkers recently reported Ad5 ORF3 and ORF6 binding to the DNAdependent protein kinase (DNA PK) (Boyer et al., 1999) , an essential element involved in controlling the end-joining mechanism in the double-strand break repair (DSBR) system (reviewed in Smith and Jackson, 1999) . Functional analyses show that ORF6, although not ORF3, can inhibit V(D)J-joining (Boyer et al., 1999) , a process that requires DNA PK. Moreover, Young and coworkers showed that both ORF3 and 6 can inhibit the repair of speci®c double-strand breaks induced by the Saccharomyces cerevisiae HO endonuclease in co-infected cells (NicolaÂ s et al., 2000) .
ORF3 and ORF6 gene products have also been found to physically associate with the E1B 55-kDa product (Leppard and Everett, 1999; Nevels et al., 1999b), a multifunctional regulator of cell cycleindependent Ad replication controlling several processes including inhibition of p53-dependent apoptosis and G1/S phase arrest, and nucleocytoplasmic mRNA transport (reviewed in Dobner and Kzhyshkowska, 2001 ). Both E4 proteins cause nuclear accumulation of 55-kDa and direct the E1B protein to dierent virusinduced structures in the nucleus (Ornelles and Shenk, 1991; Goodrum et al., 1996; KoÈ nig et al., 1999; Leppard and Everett, 1999) . ORF6-mediated E1B 55-kDa nuclear accumulation requires a functional interaction between ORF6 and 55-kDa involving a primate cell-speci®c factor (Goodrum et al., 1996) .
In addition to DNA PK and E1B 55-kDa, E4 ORF3 directly or indirectly targets cellular factors that are components of dot-like matrix-associated multiprotein complexes known as nuclear bodies (NBs) or PML oncogenic domains (PODs). It seems that Ad infection (Puvion-Dutilleul et al., 1995) , and more speci®cally ORF3, induces rearrangement of PODs into track-like formations early after infection (Carvalho et al., 1995; Doucas et al., 1996) . There are recent indications that POD-reorganization is linked to modulation of the immune response (Terris et al., 1995; Zheng et al., 1998) , and cell-cycle independent virus growth, the last also involving ORF6 and E1B 55-kDa (Goodrum and Ornelles, 1999) .
In addition to the biochemical data, both E4 ORF6 and ORF3 from subgroup C Ad5 were recently shown to have transforming and oncogenic potential. In cooperation with Ad5 E1 proteins, and synergistically with E1B, both E4 proteins substantially enhance focus formation in primary baby rat kidney (BRK) cells (Moore et al., 1996; Nevels et al., 1997 Nevels et al., , 1999b . This means that compared to cells expressing only E1A and E1B, transformed BRK cells also stably expressing E4 ORF6 and/or E4 ORF3 exhibit multiple additional properties commonly associated with advanced oncogenic transformation, including profound morphological alterations and, in the case of ORF6, dramatically accelerated tumor growth in nude mice (Moore et al., 1996; Nevels et al., 1999a,b) . The highly transformed ORF6-associated phenotypes in E1-transformed rat cells correlate with a dramatic reduction of p53 steady-state levels which are inversely correlated with E4 ORF6 expression (Nevels et al., 1999a) . It seems that E4 ORF6 and E1B 55-kDa proteins cooperate to counteract E1A-induced stabilization of p53 through accelerated p53 proteolytic degradation (Grand et al., 1994; Moore et al., 1996; Nevels et al., 1997 Nevels et al., , 1999a Querido et al., 1997 Querido et al., , 2001 Roth et al., 1998; Steegenga et al., 1998; Boyer and Ketner, 2000; Cathomen and Weitzman, 2000; Wienzek et al., 2000) , and as with many proteins, the 26S proteasome appears to be important for p53 turnover (Querido et al., 2001) . This p53 degradation also seems to depend on 55-kDa interacting with both p53 and ORF6, but occurs independently of MDM2 and p19ARF, regulators of p53 stability in mammalian cells (Roth et al., 1998; Nevels et al., 2000; Querido et al., 2001) .
Ad E4 gene function in oncogenesis B Ta Èuber and T Dobner
Functional p53 degradation maps to several regions of ORF6 (Nevels et al., 1997 (Nevels et al., , 1999a (Nevels et al., , 2000 Querido et al., 1997 Querido et al., , 2001 Roth et al., 1998; Steegenga et al., 1998; Grifman et al., 1999; Boyer and Ketner, 2000; Cathomen and Weitzman, 2000; Wienzek et al., 2000) including putative zinc-coordinating cysteine and histidine residues located in the amino-terminal p53-binding region. It is interesting to note that the region surrounding the HCHC tetrapeptide of E4 ORF6 (Figure 3 ), although not a bona ®de RING ®nger, may share similarities with RING motifs (Boyer and Ketner, 2000) . The RING ®nger, a cysteine-rich, zincchelating protein motif, can mediate binding to ubiquitin-conjugating enzymes (E2s) and ubiquitination of several unrelated proteins (Lorick et al., 1999) . Based on this observation it has been proposed that E4 ORF6 products may interact with components of the ubiquitin-conjugation machinery through their CCRmotifs leading to degradation of cellular proteins, such as p53 (Nevels et al., 2000) . In fact a recent study indicates that E4 ORF6 is part of a multi-protein complex that contains a novel Cullin-containing E3 ubiquitin ligase composed of Cullin family member Cul5, Elongins B and C, and the RING-H2 ®nger protein Rbx1 (Querido et al., submitted) . Remarkably, this complex is similar to the von Hippel-Lindau (VHL) tumor suppressor and SCF (Skp1-Cul1/Cdc53-F-box) E3 ubiquitin ligase complexes and is capable of stimulating ubiquitination of p53 in vitro in the presence of E1/E2 ubiquitin activating and conjugating enzymes (Querido et al., submitted) .
While p53 destabilization maps to multiple aminoand carboxy-terminal regions, promotion of focus formation and morphological transformation requires only the carboxy-terminal oncodomain of the E4 ORF6 protein (Figure 3) . The latter eects are apparently completely independent of p53 stability, but may involve other interactions with the tumor suppressor (Dobner et al., 1996; Nevels et al., 1997; Querido et al., 1997) . Thus, although at least two genetically distinct activities contribute to the oncogenic potential of Ad5 E4 ORF6, both activities are largely mediated through the CCR-motif and the arginine-faced amphipathic a-helix (Orlando and Ornelles, 1999) located in the carboxy-terminal region of the E4 protein (Figure 3; Nevels et al., 2000) .
The ability of E4 ORF3 to promote oncogenic cell growth, in contrast to E4 ORF6, is probably not linked to p53 function and stability, but rather to combined eects involving binding to Ad5 E1B 55-kDa protein and colocalization with PODs, although apparently not to interactions with the PML gene product (Nevels et al., 1999b) . This would ®t well with a model suggesting that ORF3-induced reorganization of PODs triggers a cascade of processes causing uncontrolled cell proliferation and neoplastic growth, particularly since PODs have recently been implicated in genomic stability (Zhong et al., 1999) .
E4 ORF6 and ORF3 also initiate focal transformation of primary BRK cells in an E1B-like fashion in cooperation with Ad5 E1A. But whereas established E1A/E1B-transformed cells consistently maintain and express the viral genes, the majority of BRK cells transformed by E1A plus either E4 ORF6 or ORF3 subsequently lack both E4-and E1A-speci®c DNA sequences (Nevels et al., 2001) . Nevertheless, some of these cells exhibit fully oncogenic phenotypes and can form tumors in nude mice, apparently in contradiction to conventional concepts of classical virus-induced Figure 3 Domains and motifs in the Ad5 E4 ORF6 protein. The amino acid sequences of the leucine-rich nuclear export signal (NES) and the arginine-rich amphipathic a-helix (a) are indicated above. CCR denotes the highly conserved cysteine-rich motif (Boyer and Ketner, 2000; Nevels et al., 2000) ; NRS denotes a carboxy-terminal nuclear retention signal (Dobbelstein et al., 1997; Orlando and Ornelles, 1999) and (a) the arginine-rich amphipathic a-helix (Orlando and Ornelles, 1999) . The conserved cysteine and histidine residues are indicated below, and numbers refer to their positions in the ORF6 amino acid sequence. Mutations that aect various processes shown on the left are indicated by black squares (histidine and cysteine residues) and triangles (amino acids in the NES and a-helix). Thin lines denote regions that have been mapped by deletions, and numbers refer to their position in the ORF6 amino acid sequence. The ORF6 oncodomain (dashed line) is shown on the bottom of the ®gure (assembled from several publications cited in the text) oncogenesis that consider the continuous expression of viral proteins necessary to sustain the transformed phenotype. Such observations spawned the`hit-andrun' model, which claims that viral molecules are indeed necessary to initiate but not to maintain cellular transformation (Nevels et al., 2001) . The fact that transient expression of E1A plus E4 ORF6 or E4 ORF3 proved to be mutagenic (Nevels et al., 2001) suggests that the viral genes mediate such`hit-and-run' transformation by inducing oncogenic mutations in cellular genes.
Although not yet understood at the molecular level, it is not unreasonable to implicate the involvement of ORF6/p53 interactions (Dobner et al., 1996) and, as discussed above, the association of both E4 proteins with the catalytic subunit of the DNA PK, which might inhibit double-strand break repair (Boyer et al., 1999; NicolaÂ s et al., 2000) .
E4 ORF6/7
The proximal gene product encoded in early region 4 is de®ned as a fusion protein of open reading frames 6 and 7 (reviewed in TaÈ uber . Evidence indicates that ORF6/7 acts as a viral transactivator complementing the function of E1A proteins to promote expression of the viral (E2) and cellular genes controlled by the E2F family of transcription factors. E2F activity is regulated in a cell cycle-dependent manner, with interactions involving the retinoblastoma gene family members pRb, p107 and p130 (reviewed in Cress and Nevins, 1996b) repressing E2F activities. Binding of the E1A proteins to Rb family members dissociates them from E2Fs (Kovesdi et al., 1986a (Kovesdi et al., ,b, 1987 Cress and Nevins, 1996a) , resulting in activation of cellular genes containing E2F-binding sites, and induction of cell cycle progression (Cress and Nevins, 1996b) . In contrast, the E4 ORF6/7 gene product binds free E2F, which then dimerizes (Obert et al., 1994) and binds with increased stability to the two inverted E2F-binding sites in the Ad5 E2 early promoter Huang and Hearing, 1989b; Marton et al., 1990; Raychaudhuri et al., 1989) and the cellular E2F-1 promoter (Schaley et al., 2000) . The induction of stabilized E2F-binding in vitro correlates with transcriptional activation of both promoters in vivo (Reichel et al., 1989; Neill et al., 1990; Neill and Nevins, 1991; O'Connor and Hearing, 1991; Obert et al., 1994; Schaley et al., 2000) . A recent study suggests that E4 ORF6/7 alone is sucient to displace pRb and p107 from E2F complexes thereby activating expression of E2 via induction of E2F-binding to the E2 early promoter, and resulting in signi®cantly enhanced replication of an E1A-defective Ad in HeLa cells .
Keeping in mind the complementary, indeed redundant functions of E1A and E4 ORF6/7 proteins in modulating E2F-mediated transcription it is interesting to note that Ad5 ORF6/7 can positively and negatively aect transformation. Ad5 ORF6/7 can partly promote the immortalization and morphological transformation of primary BRK cells in the presence of a pRb-nonbinding E1A mutant protein unable to release E2Fs from pRb complexes (Yamano et al., 1999) . Conversely, Ad5 ORF6/7 suppresses growth of untransformed rat cells through p53-dependent mechanisms (Yamano et al., 1999) , and reduces the transformation frequency of primary BRK cells if coexpressed with wild type E1A or E1A plus E1B (Nevels et al., 1997) . The growth-stimulatory activities in BRK cells involve amino acids 81 ± 150 in the carboxy-terminus and an additional region comprising amino acids 39 ± 58 from ORF6, while the growth-inhibitory activities map to the carboxy-terminal 59 amino acids (Yamano et al., 1999) . Since the carboxy-terminal segment contains the regions involved in E2F-interaction and possibly E2F-1 release from pRb complexes, both positive and negative eects may be linked to E2F-1, which can either act as an oncogene or a tumor suppressor depending on the cellular context (Johnson et al., 1994; Singh et al., 1994; Xu et al., 1995; Field et al., 1996) .
Conclusions
The multiple functions and variety of protein partners interacting with dierent gene products encoded by the E4 region of human Ads not only shed light on processes important for the viral life cycle but on how viral interference with normal cell-control networks can lead to oncogenic transformation. It is now becoming clear that the transforming potential of human Ads is not determined by the classical E1A and E1B oncoproteins alone. As understood at present the growth-transforming activities of the E4 gene products described here apparently operate independently of E1 (E4 ORF1) or can replace the transforming functions of E1B (E4 ORF3 or E4 ORF6) through novel mechanisms that modulate the function of key cellular regulators controlling cell signaling, gene expression, apoptosis and DNA repair. Given their growth-transforming activities and mutagenic potential there is clearly an urgent need to anticipate any undesired consequences that expression of E4 ORFs 1, 3 and 6 in an Ad vector backbone may have on viral growth and viral infection, speci®cally in the context of gene therapy. Thus further clari®cation of the molecular mechanisms contributing to their transforming and mutagenic potential, as well as a better understanding of the functions encoded in the E4 region should not only lead to greater insights into oncogenic processes but certainly help to design highly eective and safe adenovirus vectors for human gene therapy in the future.
